TD Cowen analyst Steve Scala maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of $45.00. The ...
Though GSK is definitely not the best large-cap drugmaker to have in one's portfolio, we believe there is potential for its ...
Some antibody-drug conjugates may cause such significant ocular toxicity that patients have vision damage or have to stop ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback